Cargando…

External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer

BACKGROUND: Data for selpercatinib [a selective REarranged during Transfection (RET) inhibitor] from a single-arm trial (LIBRETTO-001, NCT03157128) in RET-fusion-positive advanced/metastatic non-small-cell lung cancer (NSCLC) were used in combination with external data sources to estimate comparativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolfo, C., Hess, L.M., Jen, M.-H., Peterson, P., Li, X., Liu, H., Lai, Y., Sugihara, T., Kiiskinen, U., Vickers, A., Summers, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434413/
https://www.ncbi.nlm.nih.gov/pubmed/35930972
http://dx.doi.org/10.1016/j.esmoop.2022.100551
_version_ 1784780868758274048
author Rolfo, C.
Hess, L.M.
Jen, M.-H.
Peterson, P.
Li, X.
Liu, H.
Lai, Y.
Sugihara, T.
Kiiskinen, U.
Vickers, A.
Summers, Y.
author_facet Rolfo, C.
Hess, L.M.
Jen, M.-H.
Peterson, P.
Li, X.
Liu, H.
Lai, Y.
Sugihara, T.
Kiiskinen, U.
Vickers, A.
Summers, Y.
author_sort Rolfo, C.
collection PubMed
description BACKGROUND: Data for selpercatinib [a selective REarranged during Transfection (RET) inhibitor] from a single-arm trial (LIBRETTO-001, NCT03157128) in RET-fusion-positive advanced/metastatic non-small-cell lung cancer (NSCLC) were used in combination with external data sources to estimate comparative efficacy [objective response rate (ORR), progression-free survival, and overall survival (OS)] in first- and second-line treatment settings. METHODS: Patient-level data were obtained from a de-identified real-world database. Patients diagnosed with advanced/metastatic NSCLC with no prior exposure to a RET inhibitor and one or more prior line of therapy were eligible. Additionally, individual patient-level data (IPD) were obtained from the pemetrexed + platinum arm of KEYNOTE-189 (NCT03950674, first line) and the docetaxel arm of REVEL (NCT01168973, post-progression). Patients were matched using entropy balancing, doubly robust method, and propensity score approaches. For patients with unknown/negative RET status, adjustment was made using a model fitted to IPD from a real-world database. RESULTS: In first-line unadjusted analyses of the real-world control, ORR was 87.2% for LIBRETTO-001 versus 66.7% for those with RET-positive NSCLC (P = 0.06). After adjustment for unknown RET status and other patient characteristics, selpercatinib remained significantly superior versus the real-world control for all outcomes (all P < 0.001 except unadjusted RET-fusion-positive cohort). Similarly, outcomes were significantly improved versus clinical trial controls (all P < 0.05). CONCLUSIONS: Findings suggest improvement in outcomes associated with selpercatinib treatment versus the multiple external control cohorts, but should be interpreted with caution. Data were limited by the rarity of RET, lack of mature OS data, and uncertainty from assumptions to create control arms from external data.
format Online
Article
Text
id pubmed-9434413
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94344132022-09-02 External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer Rolfo, C. Hess, L.M. Jen, M.-H. Peterson, P. Li, X. Liu, H. Lai, Y. Sugihara, T. Kiiskinen, U. Vickers, A. Summers, Y. ESMO Open Original Research BACKGROUND: Data for selpercatinib [a selective REarranged during Transfection (RET) inhibitor] from a single-arm trial (LIBRETTO-001, NCT03157128) in RET-fusion-positive advanced/metastatic non-small-cell lung cancer (NSCLC) were used in combination with external data sources to estimate comparative efficacy [objective response rate (ORR), progression-free survival, and overall survival (OS)] in first- and second-line treatment settings. METHODS: Patient-level data were obtained from a de-identified real-world database. Patients diagnosed with advanced/metastatic NSCLC with no prior exposure to a RET inhibitor and one or more prior line of therapy were eligible. Additionally, individual patient-level data (IPD) were obtained from the pemetrexed + platinum arm of KEYNOTE-189 (NCT03950674, first line) and the docetaxel arm of REVEL (NCT01168973, post-progression). Patients were matched using entropy balancing, doubly robust method, and propensity score approaches. For patients with unknown/negative RET status, adjustment was made using a model fitted to IPD from a real-world database. RESULTS: In first-line unadjusted analyses of the real-world control, ORR was 87.2% for LIBRETTO-001 versus 66.7% for those with RET-positive NSCLC (P = 0.06). After adjustment for unknown RET status and other patient characteristics, selpercatinib remained significantly superior versus the real-world control for all outcomes (all P < 0.001 except unadjusted RET-fusion-positive cohort). Similarly, outcomes were significantly improved versus clinical trial controls (all P < 0.05). CONCLUSIONS: Findings suggest improvement in outcomes associated with selpercatinib treatment versus the multiple external control cohorts, but should be interpreted with caution. Data were limited by the rarity of RET, lack of mature OS data, and uncertainty from assumptions to create control arms from external data. Elsevier 2022-08-02 /pmc/articles/PMC9434413/ /pubmed/35930972 http://dx.doi.org/10.1016/j.esmoop.2022.100551 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Rolfo, C.
Hess, L.M.
Jen, M.-H.
Peterson, P.
Li, X.
Liu, H.
Lai, Y.
Sugihara, T.
Kiiskinen, U.
Vickers, A.
Summers, Y.
External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
title External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
title_full External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
title_fullStr External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
title_full_unstemmed External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
title_short External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
title_sort external control cohorts for the single-arm libretto-001 trial of selpercatinib in ret+ non-small-cell lung cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434413/
https://www.ncbi.nlm.nih.gov/pubmed/35930972
http://dx.doi.org/10.1016/j.esmoop.2022.100551
work_keys_str_mv AT rolfoc externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT hesslm externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT jenmh externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT petersonp externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT lix externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT liuh externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT laiy externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT sugiharat externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT kiiskinenu externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT vickersa externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer
AT summersy externalcontrolcohortsforthesinglearmlibretto001trialofselpercatinibinretnonsmallcelllungcancer